Baidu
map

拜耳拟以约29亿美元收购挪威制药公司Algeta

2014-01-24 佚名 生物谷

近日,挪威制药公司Algeta与拜耳公司已达成一项协议,拜耳拟以大约29亿美元收购挪威制药公司Algeta。该项交易预计于2014年第一季度完成。Algeta公司估值约为24亿美元,其开发的前列腺癌治疗药物Xofigo最近获得批准。Xofigo于上个月在欧洲获得批准,而在美国于今年(2013年)5月份获得批准,比预计日期提前了三个月。该治疗药物适用于症状性骨转移及无已知内脏转移的去势抵抗性前列腺癌



近日,挪威制药公司Algeta与拜耳公司已达成一项协议,拜耳拟以大约29亿美元收购挪威制药公司Algeta。该项交易预计于2014年第一季度完成。Algeta公司估值约为24亿美元,其开发的前列腺癌治疗药物Xofigo最近获得批准。

Xofigo于上个月在欧洲获得批准,而在美国于今年(2013年)5月份获得批准,比预计日期提前了三个月。该治疗药物适用于症状性骨转移及无已知内脏转移的去势抵抗性前列腺癌男性患者的治疗,其今年(2013年)第三季度的销售额大约为1200万欧元。Algeta公司董事长Andrew Kay上个月说,由于美国国家癌症网络的快速认可,这款药物已显示出良好增长势头。此外在Algeta的产品研发线上还有其它放射性药物,包括一个乳腺癌治疗药物。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775787, encodeId=cce21e75787d6, content=<a href='/topic/show?id=34bb56501b5' target=_blank style='color:#2F92EE;'>#挪威制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56501, encryptionId=34bb56501b5, topicName=挪威制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06f038803110, createdName=zsyan, createdTime=Thu Aug 21 13:11:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318424, encodeId=3a261318424be, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539197, encodeId=d1c9153919e34, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591500, encodeId=c3a4159150036, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775787, encodeId=cce21e75787d6, content=<a href='/topic/show?id=34bb56501b5' target=_blank style='color:#2F92EE;'>#挪威制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56501, encryptionId=34bb56501b5, topicName=挪威制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06f038803110, createdName=zsyan, createdTime=Thu Aug 21 13:11:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318424, encodeId=3a261318424be, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539197, encodeId=d1c9153919e34, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591500, encodeId=c3a4159150036, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
    2014-01-26 ying_wu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775787, encodeId=cce21e75787d6, content=<a href='/topic/show?id=34bb56501b5' target=_blank style='color:#2F92EE;'>#挪威制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56501, encryptionId=34bb56501b5, topicName=挪威制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06f038803110, createdName=zsyan, createdTime=Thu Aug 21 13:11:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318424, encodeId=3a261318424be, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539197, encodeId=d1c9153919e34, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591500, encodeId=c3a4159150036, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
    2014-01-26 HNYYM
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775787, encodeId=cce21e75787d6, content=<a href='/topic/show?id=34bb56501b5' target=_blank style='color:#2F92EE;'>#挪威制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56501, encryptionId=34bb56501b5, topicName=挪威制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06f038803110, createdName=zsyan, createdTime=Thu Aug 21 13:11:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318424, encodeId=3a261318424be, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539197, encodeId=d1c9153919e34, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591500, encodeId=c3a4159150036, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Sun Jan 26 05:11:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]

相关资讯

拜耳制药新药Gadavist通过FDA批准

3月14日,美国食品药品管理局(FDA)批准Gadavist(钆布醇)——一个含钆的造影剂,用于患者中枢神经系统的磁共振成像(MRI)检查。据悉,Gadavist是FDA批准的用于中枢神经系统磁共振成像的第六个含钆造影剂(GBCAs),适用于两岁及以上的儿童和成人。 Gadavist用于中枢神经系统MRI检查的对比增强成像,成像时可将大脑与血流分离,帮助检测和显现破坏细胞屏障的病变。此外,它还

拜耳与北大联合成立新药研发和转化研究中心

拜耳医药保健和北京大学1月8日正式签署全面战略合作协议,开展为期三年的新药研发和转化合作。根据该协议,合作双方将在北京大学建立联合研究中心,即拜耳医药保健-北京大学新药研发和转化研究中心(BPC/TRDD)。签署仪式在北京大学博雅国际会议中心举办,北京大学副校长陈十一博士和拜耳医药保健执行委员会成员、全球药物研发总裁AndreasBusch教授出席了该仪式。 “与来自全球行业和学术机构的创新

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

拜耳(Bayer)上周末宣布,药物regorafenib获得了欧盟委员会(EC)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准将regorafenib用于既往治疗过或不适用于当前可用疗法(包括基于氟尿嘧啶的化疗,抗VEGF疗法、抗EGFR疗法)的转移性结直肠癌(mCRC)成人患者的治疗。预计EC将于2013年第三季度作出审查决定。 CHMP的积极意见,是基于关键性III期CORREC

拜耳向EMA及FDA提交多吉美治疗甲状腺癌的上市许可申请(MA)

拜耳(Bayer)昨日宣布,已向欧洲药品管理局(EMA)及FDA提交了有关口服多激酶抑制剂多吉美(Nexavar,通用名:sorafenib,索拉非尼)用于局部晚期或转移性放射性碘(RAI)难治性分化型甲状腺癌治疗的上市许可申请(MA)。 相关监管文件的提交,是基于III期DECISION临床试验的数据,结果表明,与安慰剂相比,sorafenib显著延长了患者的疾病无进展生存期(PFS)

FDA优先审查利伐沙班和阿哌沙班新适应证

 FDA授予新口服抗凝药利伐沙班(Xarelto,拜耳)联合标准抗血小板治疗用于减少急性冠脉综合征患者的心血管事件这一额外适应证的优先审查权。这意味着该机构将在收到补充新药申请(NDA)提交报告后6个月内(而非标准的10个月审批周期)完成对审查。 同时,FDA声称将把阿哌沙班(Eliquis,辉瑞/百时美-施贵宝)用于预防房颤患者的卒中和全身栓塞的NDA审查日期延长3个月。当2011年

拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据

2012年6月4日,Onyx制药公司今天宣布,在伊马替尼(imatinib)和舒尼替尼(sunitinib)治疗无效的转移性和/或手术不能切除的胃肠道间质瘤(GIST)患者中开展的评价regorafenib的III期GRID试验,达到了预期主要终点(无进展生存期,PFS,HR=0.27,p<0.0001)。regorafenib组平均PFS为4.8个月,对照组为0.9个月。 "GIST,由

Baidu
map
Baidu
map
Baidu
map